Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Uniseed is Australia's longest-running venture capital fund, established to assist researchers in commercializing their innovations. Founded in 2000, the firm is headquartered in Australia and collaborates with partner research organizations and UniSuper, a prominent Australian superannuation fund. Uniseed's mission is to transform research ideas into marketable products and services, addressing significant market problems while creating a positive community impact.
The organization has launched multiple funds, including its third and largest fund in 2015, which received commitments from various universities and research institutions. Uniseed has built a reputation for supporting innovations that have the potential to change industries, particularly in the biotech, healthcare, and SaaS sectors. The firm has a diverse portfolio and a strong track record of successful exits, showcasing its effectiveness in the venture capital space.
Uniseed invests primarily in seed-stage companies across a broad range of technology sectors, including biotech, healthcare, and SaaS. The firm provides seed capital to researchers and startups, emphasizing collaboration, expert guidance, and access to extensive networks to de-risk innovations from both technical and commercial perspectives. Uniseed's investment strategy includes syndicating promising deals with co-investors, which allows for shared risk and enhanced support for portfolio companies.
The organization seeks to partner with founders who demonstrate a strong commitment to their innovations and possess the ability to navigate the complexities of bringing research to market. Uniseed's approach is characterized by its focus on transforming research into viable commercial products, ensuring that the innovations it supports can effectively address real-world challenges.
Uniseed has invested in numerous startups, achieving notable exits that include Fibrotech, Spinifex, and Hatchtech. These companies have made significant contributions to their respective fields, demonstrating the effectiveness of Uniseed's investment strategy. In addition to these exits, Uniseed has supported companies that have launched innovative products, such as Q-Sera, which developed the RAPClot™ rapid serum blood collection tube technology, and ENA Respiratory, known for the INNA-051 nasal spray designed for viral respiratory infections.
The firm’s portfolio reflects its commitment to fostering innovation in sectors that have a substantial impact on health and technology. Uniseed continues to seek out and support startups that are poised to make a difference in their industries.
Alastair Hick - CEO, brings extensive experience in venture capital and innovation commercialization.
Laura Droessler-Dansie - Investment Manager - Technology, based in Sydney, specializes in technology investments.
John Kurek - Investment Director - Biotechnology, located in Melbourne, has a strong background in biotech investments.
Aleta Knowles - Investment Manager - Biotechnology, also based in Sydney, focuses on supporting biotech startups.
Jeffrey Bourne - Investment Manager - Technology, located in Melbourne, has expertise in technology-driven ventures.
Rhiannon Black - Business Operations Specialist, supports operational aspects of the firm.
Richard Symons - Chief Financial Officer, manages the financial operations of Uniseed.
Alex Mahoney - Investment Analyst, provides analytical support for investment decisions.
Submit your pitch through their website's contact form.
In 2023, Uniseed has continued to support startups and researchers, focusing on transforming research ideas into marketable products and services. The firm has highlighted its notable portfolio companies and successful exits, including Fibrotech, Spinifex, and Hatchtech, showcasing its commitment to fostering innovation in the biotech, healthcare, and SaaS sectors.
Uniseed's third fund, launched in 2015, remains its largest, with commitments from various universities and research institutions, reflecting ongoing support for the commercialization of research innovations.
What are Uniseed's investment criteria?
Uniseed focuses on seed-stage investments in technology sectors, particularly biotech, healthcare, and SaaS. The firm looks for innovative research ideas that can be commercialized and address significant market needs.
How can startups apply or pitch to Uniseed?
Startups can reach out to Uniseed through their contact page or by connecting with their commercialization offices. A detailed pitch deck outlining the innovation, market potential, and team is recommended.
What makes Uniseed different from other venture funds?
Uniseed is distinguished by its long-standing commitment to supporting researchers in commercializing their innovations. The firm emphasizes collaboration and provides access to expert guidance and networks to help de-risk innovations.
What is Uniseed's geographic scope?
Uniseed primarily invests in Australia, collaborating with local universities and research institutions to identify promising innovations.
What is Uniseed's post-investment involvement like?
Uniseed actively supports its portfolio companies through mentorship, operational guidance, and access to networks that can facilitate growth and scaling of their innovations.
What is the typical check size for Uniseed's investments?
Uniseed provides seed capital, with check sizes varying based on the specific needs of the startup and the potential of the innovation being funded.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.